Molecular Mechanism of Protein Kinase Cbeta-Mediated Cholesterol Homeostasis

蛋白激酶Cbeta介导的胆固醇稳态的分子机制

基本信息

  • 批准号:
    7894724
  • 负责人:
  • 金额:
    $ 37.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-12-06 至 2013-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Every year in the United States nearly 1 million deaths occur among the 7 million people affected with cardiovascular diseases. The dominant underlying factor for this disease includes elevated plasma low density lipoprotein (LDL)-cholesterol levels in association with hypertriglyceridemia, abdominal obesity, or insulin resistance. The plasma levels of LDL are strongly influenced by dietary cholesterol and body's ability to store and metabolize ingested cholesterol. Considering that adipose tissue accumulates one of the largest pools of exchangeable free cholesterol, there is no information available regarding the role and regulation of adipose LDL receptors and its relationship to whole body cholesterol homeostasis. Also, our knowledge of the signaling pathway controlling adipose endocrine and lipo-metabolic functions through sterol-response element binding protein-1c (SREBP-1c) is limited, as is the role of this kinase in diet-induced atherosclerosis. We previously showed, for the first time, involvement of specific isoforms of protein kinase C (PKC) in regulating hepatic LDL receptor expression. In order to extend these studies to whole animal, we have been studying consequences of PKCbeta deficiency on lipid homeostasis. Based on our most recent observations linking PKCbeta deficiency to reduced plasma LDL levels, increased adipose nuclear SREBP-1c resulting in LDL receptor induction, and changes in plasma adipokines levels, we propose that PKCbeta plays a critical role in cholesterol homeostasis by regulating adipose SREBP-1c processing, thus regulating genes of lipid homeostasis and atherosclerosis. In Specific Aim 1, role of PKCbeta in LDL homeostasis will be established by evaluating effects of PKCbeta deficiency on hepatic biosynthesis and clearance, as well as adipose uptake of plasma LDL. To understand the molecular basis, we will also determine PKCbeta-dependent changes in the adipose gene expression and whether overexpression of adipose PKCbeta rescues the phenotype or adipose-specific PKCbeta deficiency alone can account for this phenotype. Specific Aim beta will define the nuclear and cytoplasmic events at the molecular level by which PKCbeta deficiency promotes nuclear accumulation of SREBP-1c and induction of adipose LDL receptors, without affecting hepatic LDL receptor expression. Finally, Specific Aim 3 will investigate the role of PKCbeta in cholesterol-rich-diet-induced atherosclerosis in PKCbeta-/- x ApoE-/- mice under diabetic or nondiabetic conditions. We already have these mice and initial results are very encouraging and have the potential to provide the molecular basis of diabetes-induced atherosclerosis and an alternative to statin. The proposed studies will not only establish the role of PKCbeta in regulating whole body cholesterol homeostasis, but will also identify genes regulated by this kinase, to correlate regulatory mechanisms to animal physiology. Accomplishment of the above aims will unravel a central signaling component that may control dyslipidemia and atherosclerosis by regulating adipose tissue physiology; modulation of its activity may be the preferable mode for the treatment of lipid disorders and prevention of atherosclerosis in the beta1st century. PUBLIC HEALTH RELEVANCE: Cardiovascular disease remains the leading cause of death in industrialized nations despite major advances in its diagnosis, treatment, and prevention. The underlying aetiology is not clarified, but includes a strong genetic component as well as lifestyle factors such as physical inactivity, dietary habits and smoking. While there has been a trend over the last half century showing a general decline in the age-adjusted death rates of heart disease and stroke, the increasing epidemics of obesity, followed closely by insulin resistance and diabetes, will likely slow the decline and reverse this trend. It is both necessary and timely to define roles of protein kinase Cbeta isoform that simultaneously modify all risk factors. The greatest potential for arresting this epidemic is likely to come through a clearer understanding of its molecular pathogenesis to develop rational and mechanism based therapy.
描述(由申请人提供):在美国,每年有近100万人死亡,其中700万人患有心血管疾病。这种疾病的主要潜在因素包括与高脂血症、腹部肥胖或胰岛素抵抗相关的血浆低密度脂蛋白(LDL)-胆固醇水平升高。LDL的血浆水平受到饮食胆固醇和身体储存和代谢摄入胆固醇的能力的强烈影响。考虑到脂肪组织积累了最大的可交换游离胆固醇库之一,没有关于脂肪LDL受体的作用和调节及其与全身胆固醇稳态关系的信息。此外,我们对通过固醇反应元件结合蛋白-1c(SREBP-1c)控制脂肪内分泌和脂代谢功能的信号通路的了解有限,这种激酶在饮食诱导的动脉粥样硬化中的作用也是有限的。我们先前表明,第一次,参与特定亚型的蛋白激酶C(PKC)在调节肝脏LDL受体的表达。为了将这些研究扩展到整个动物,我们一直在研究PKC β缺乏对脂质稳态的影响。基于我们最近的观察,PKC β缺乏与血浆LDL水平降低,脂肪核SREBP-1c增加导致LDL受体诱导,以及血浆脂肪因子水平的变化有关,我们认为PKC β通过调节脂肪SREBP-1c加工,从而调节脂质稳态和动脉粥样硬化的基因,在胆固醇稳态中起关键作用。在特定目标1中,将通过评价PKC β缺乏对肝脏生物合成和清除以及血浆LDL的脂肪摄取的影响,确定PKC β在LDL稳态中的作用。为了了解分子基础,我们还将确定脂肪基因表达中PKC β依赖性的变化,以及脂肪PKC β的过度表达是否可以挽救表型或脂肪特异性PKC β缺乏单独可以解释这种表型。特异性Aim β将在分子水平上定义细胞核和细胞质事件,通过该事件,PKC β缺乏促进SREBP-1c的核蓄积和脂肪LDL受体的诱导,而不影响肝脏LDL受体表达。最后,具体目标3将研究糖尿病或非糖尿病条件下PKC β-/- x ApoE-/-小鼠中PKC β在高胆固醇饮食诱导的动脉粥样硬化中的作用。我们已经有了这些小鼠,初步结果非常令人鼓舞,并有可能提供糖尿病诱导的动脉粥样硬化的分子基础和他汀类药物的替代品。拟议的研究不仅将确立PKC β在调节全身胆固醇稳态中的作用,而且还将鉴定受该激酶调节的基因,以将调节机制与动物生理学相关联。上述目标的实现将揭示可通过调节脂肪组织生理学来控制血脂异常和动脉粥样硬化的中心信号传导组分;调节其活性可能是世纪治疗脂质紊乱和预防动脉粥样硬化的优选模式。公共卫生关系:心血管疾病仍然是工业化国家的主要死因,尽管其诊断,治疗和预防取得了重大进展。潜在的病因尚不清楚,但包括一个强大的遗传成分以及生活方式因素,如缺乏运动,饮食习惯和吸烟。虽然在过去的半个世纪中,心脏病和中风的年龄调整死亡率出现了普遍下降的趋势,但肥胖症的日益流行,紧随其后的是胰岛素抵抗和糖尿病,可能会减缓下降并扭转这一趋势。明确蛋白激酶C β亚型同时修饰所有危险因素的作用是必要的,也是及时的。控制这种流行病的最大潜力可能是通过更清楚地了解其分子发病机制来开发合理的和基于机制的治疗。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Exercise protects against diet-induced insulin resistance through downregulation of protein kinase Cβ in mice.
  • DOI:
    10.1371/journal.pone.0081364
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Rao X;Zhong J;Xu X;Jordan B;Maurya S;Braunstein Z;Wang TY;Huang W;Aggarwal S;Periasamy M;Rajagopalan S;Mehta K;Sun Q
  • 通讯作者:
    Sun Q
Loss of protein kinase Cbeta function protects mice against diet-induced obesity and development of hepatic steatosis and insulin resistance.
  • DOI:
    10.1002/hep.22815
  • 发表时间:
    2009-05
  • 期刊:
  • 影响因子:
    13.5
  • 作者:
    Huang, Wei;Bansode, Rishipal;Mehta, Madhu;Mehta, Kama D.
  • 通讯作者:
    Mehta, Kama D.
Modulation of Hepatic Protein Kinase Cβ Expression in Metabolic Adaptation to a Lithogenic Diet.
Protein kinase C-beta: An emerging connection between nutrient excess and obesity.
  • DOI:
    10.1016/j.bbalip.2014.07.011
  • 发表时间:
    2014-10
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Neil K Mehta;K. Mehta
  • 通讯作者:
    Neil K Mehta;K. Mehta
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KAMAL D MEHTA其他文献

KAMAL D MEHTA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KAMAL D MEHTA', 18)}}的其他基金

PKCbeta mediates dietary fat/cholesterol-induced cholesterol homeostasis
PKCbeta 介导膳食脂肪/胆固醇诱导的胆固醇稳态
  • 批准号:
    9368518
  • 财政年份:
    2017
  • 资助金额:
    $ 37.5万
  • 项目类别:
Role of PKCbeta in Diet-induced Hypercholesterolemia
PKCbeta 在饮食引起的高胆固醇血症中的作用
  • 批准号:
    7150032
  • 财政年份:
    2004
  • 资助金额:
    $ 37.5万
  • 项目类别:
Role of PKCbeta in Diet-induced Hypercholesterolemia
PKCbeta 在饮食引起的高胆固醇血症中的作用
  • 批准号:
    6857486
  • 财政年份:
    2004
  • 资助金额:
    $ 37.5万
  • 项目类别:
Role of PKCbeta in Diet-induced Hypercholesterolemia
PKCbeta 在饮食引起的高胆固醇血症中的作用
  • 批准号:
    7326829
  • 财政年份:
    2004
  • 资助金额:
    $ 37.5万
  • 项目类别:
Role of PKCbeta in Diet-induced Hypercholesterolemia
PKCbeta 在饮食引起的高胆固醇血症中的作用
  • 批准号:
    6987879
  • 财政年份:
    2004
  • 资助金额:
    $ 37.5万
  • 项目类别:
Molecular Mechanism of Protein Kinase Cbeta-Mediated Cholesterol Homeostasis
蛋白激酶Cbeta介导的胆固醇稳态的分子机制
  • 批准号:
    7653553
  • 财政年份:
    2004
  • 资助金额:
    $ 37.5万
  • 项目类别:
Mechanisms of p42/44MAPK-induced LDL receptor expression
p42/44MAPK诱导LDL受体表达的机制
  • 批准号:
    6573814
  • 财政年份:
    2001
  • 资助金额:
    $ 37.5万
  • 项目类别:
Mechanisms of p42/44MAPK-induced LDL receptor expression
p42/44MAPK诱导LDL受体表达的机制
  • 批准号:
    6656862
  • 财政年份:
    2001
  • 资助金额:
    $ 37.5万
  • 项目类别:
Mechanisms of p42/44MAPK-induced LDL receptor expression
p42/44MAPK诱导LDL受体表达的机制
  • 批准号:
    6537871
  • 财政年份:
    2001
  • 资助金额:
    $ 37.5万
  • 项目类别:
Mechanisms of p42/44MAPK-induced LDL receptor expression
p42/44MAPK诱导LDL受体表达的机制
  • 批准号:
    6773909
  • 财政年份:
    2001
  • 资助金额:
    $ 37.5万
  • 项目类别:

相似海外基金

Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    8077875
  • 财政年份:
    2010
  • 资助金额:
    $ 37.5万
  • 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    7866149
  • 财政年份:
    2010
  • 资助金额:
    $ 37.5万
  • 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    8589822
  • 财政年份:
    2010
  • 资助金额:
    $ 37.5万
  • 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    8305149
  • 财政年份:
    2010
  • 资助金额:
    $ 37.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了